Lisata Therapeutics (NASDAQ:LSTA) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA) in a report issued on Tuesday, Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock.

Lisata Therapeutics Trading Down 6.6 %

LSTA stock opened at $2.96 on Tuesday. The company has a 50 day moving average of $2.93 and a two-hundred day moving average of $2.81. Lisata Therapeutics has a 12-month low of $1.95 and a 12-month high of $4.53.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.20. Equities research analysts expect that Lisata Therapeutics will post -3.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. BML Capital Management LLC grew its holdings in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 10.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 269,839 shares of the company’s stock after purchasing an additional 26,000 shares during the quarter. Lisata Therapeutics comprises 0.6% of BML Capital Management LLC’s portfolio, making the stock its 24th biggest holding. BML Capital Management LLC owned approximately 3.31% of Lisata Therapeutics worth $737,000 at the end of the most recent quarter. 8.94% of the stock is owned by institutional investors and hedge funds.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.